
Global Blood Therapeutics GBT
Quarterly report 2022-Q2
added 08-08-2022
Global Blood Therapeutics Interest Expense 2011-2026 | GBT
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Global Blood Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -14.9 M | -4.38 M | 14.5 M | 8.55 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.5 M | -14.9 M | 941 K |
Quarterly Interest Expense Global Blood Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -6.55 M | -7.99 M | - | -3.69 M | -3.49 M | -3.44 M | - | -1.57 M | -804 K | 426 K | - | 4.2 M | 3.48 M | 3.6 M | - | 2.41 M | 2.12 M | 1.14 M | - | 623 K | 547 K | 389 K | - | 159 K | 131 K | 117 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.2 M | -7.99 M | -410 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Alterity Therapeutics Limited
ATHE
|
2.28 K | $ 3.5 | -5.79 % | $ 8.42 B | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
1.44 M | - | 4.14 % | $ 49.1 M | ||
|
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | ||
|
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B | ||
|
Applied Therapeutics
APLT
|
-27 K | - | - | $ 8.42 M | ||
|
BioNTech SE
BNTX
|
14.2 M | $ 97.54 | 2.14 % | $ 27.2 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
23 K | $ 20.22 | -0.76 % | $ 945 M | ||
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
58 K | $ 1.39 | -0.43 % | $ 357 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
Allakos
ALLK
|
8 K | - | - | $ 28.6 M | ||
|
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
227 K | $ 2.99 | 2.4 % | $ 4.92 M | ||
|
Aquestive Therapeutics
AQST
|
6.55 M | $ 4.13 | 1.23 % | $ 442 M | ||
|
Aravive
ARAV
|
2.84 M | - | -13.39 % | $ 1.45 M | ||
|
Arcutis Biotherapeutics
ARQT
|
443 K | $ 24.23 | 0.08 % | $ 3.08 B | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Celldex Therapeutics
CLDX
|
927 K | $ 32.58 | 1.05 % | $ 2.16 B | ||
|
Autolus Therapeutics plc
AUTL
|
36.7 M | $ 1.5 | 0.34 % | $ 399 M | ||
|
Cidara Therapeutics
CDTX
|
5.81 M | - | - | $ 1.41 B | ||
|
Aytu BioScience
AYTU
|
-512 K | $ 2.55 | - | $ 16 M | ||
|
InflaRx N.V.
IFRX
|
2.69 K | $ 1.02 | 2.0 % | $ 152 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-93 K | - | -2.5 % | $ 5.88 M | ||
|
BeiGene, Ltd.
BGNE
|
-42.6 M | - | 0.49 % | $ 251 B | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
Akari Therapeutics, Plc
AKTX
|
100 K | $ 3.83 | - | $ 258 B | ||
|
Allena Pharmaceuticals
ALNA
|
-38 K | - | 3.16 % | $ 1.9 M | ||
|
Baudax Bio
BXRX
|
1.36 M | - | 0.59 % | $ 63 K | ||
|
Cabaletta Bio
CABA
|
2 M | $ 3.23 | 3.19 % | $ 325 M | ||
|
Alpine Immune Sciences
ALPN
|
476 K | - | - | $ 2.17 B | ||
|
CymaBay Therapeutics
CBAY
|
18.9 M | - | - | $ 3.45 B | ||
|
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M |